Mechanisms of Resistance to Therapy in Acute Myeloid Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (1 April 2022) | Viewed by 3254
Special Issue Editors
Interests: acute myeloid leukemia (AML); leukemic stem cell (LSC); minimal residual disease (MRD)
Interests: drug resistance; measurable minimal disease; proteasome inhibitors; splicing; clonal evolution
Special Issue Information
Dear Colleagues,
At present, the first-line treatment for acute myeloid leukemia (AML) is based on daunorubicin or idarubicin and cytosine arabinoside. Although this treatment induces complete remission in the majority of patients, many face a relapse (adaptive resistance) or have refractory disease (primary resistance). Moreover, older patients are often unfit for cytotoxic-based treatment. The major therapeutic advances made over the years for AML patients have involved improvements in supportive care rather than the introduction of novel therapeutics. However, finally, after many years, a total of eight targeted agents, guided by our knowledge of the unique molecular landscape of the individual AML patient, have been approved for the treatment of AML. However, still the major problem with these targeted therapies is that many patients obtain an remission but retain residual tumor cells (minimal residual disease, MRD) that can develop into recurrence. Leukemia cells with stem cell features, named leukemic stem cells (LSCs), that reside within MRD are thought to be at the origin of AML relapse. This Special Issue will elaborate on the mechanisms of resistance to therapy in AML, including the role of signaling pathways, metabolism, the epigenome, “stemness”, integrins, the immune system, and the microenvironment.
Dr. Linda SmitProf. Dr. Jacqueline Cloos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- resistance to therapy
- minimal residual disease
- leukemic stem cells
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
